Most recent news

  • February 13, 2023

    Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

  • April 26, 2022

    Virpax Successfully Completes Initial Preclinical Studies for VRP324

  • March 31, 2022

    Virpax Pharmaceuticals Reports 2021 Year-End Results

  • March 22, 2022

    Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™

  • March 15, 2022

    Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

  • February 15, 2022

    News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

  • February 10, 2022

    Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

  • January 18, 2022

    Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

  • January 4, 2022

    Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

  • December 28, 2021

    Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

  • December 20, 2021

    Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

  • December 8, 2021

    Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

  • November 15, 2021

    Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments

  • November 10, 2021

    Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

  • October 6, 2021

    Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™

BUSINESS INQUIRIES

Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
610.727.4597
‍info@virpaxpharma.com

INVESTOR INQUIRIES

Betsy Brod
Affinity Growth Advisors
‍betsy.brod@affinitygrowth.com

MEDIA INQUIRIES

Public Relations
Virpax Pharmaceuticals, Inc.
‍pr@virpaxpharma.com